NewAmsterdam Pharma Co N.V.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
NAMS$19.00+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31,2026 | December 31,2025 | |
|---|---|---|
| (In thousands of USD) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | 457,607 | 490,002 |
| Prepayments and other receivables | 20,603 | 38,138 |
| Marketable securities, current | 178,498 | 146,239 |
| Restricted cash | 1,336 | 1,321 |
| Total current assets | 658,044 | 675,700 |
| Marketable securities, net of current portion | 71,239 | 92,609 |
| Property, plant and equipment, net | 379 | 383 |
| Operating right of use asset | 21 | 185 |
| Intangible assets | 375 | 407 |
| Long term prepaid expenses | 2,585 | — |
| Total assets | 732,643 | 769,284 |
| Liabilities and Shareholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 8,090 | 8,970 |
| Accrued expenses and other current liabilities | 5,092 | 15,422 |
| Deferred revenue, current | 3,987 | 3,987 |
| Lease liability, current | 23 | 136 |
| Derivative warrant liabilities | 50,229 | 57,272 |
| Total current liabilities | 67,421 | 85,787 |
| Lease liability, net of current portion | — | 66 |
| Total liabilities | 67,421 | 85,853 |
| Commitments and contingencies (Note 12) | ||
| Shareholders' Equity: | ||
| Ordinary shares, €0.12 par value; 400,000,000 shares authorized; 116,641,656 and 114,399,326 shares issued and outstanding at March 31, 2026 and December 31, 2025 respectively | 14,594 | 14,278 |
| Additional paid-in capital | 1,457,238 | 1,426,750 |
| Accumulated loss | (810,831) | (762,390) |
| Accumulated other comprehensive income | 4,221 | 4,793 |
| Total shareholders' equity | 665,222 | 683,431 |
| Total liabilities and shareholders' equity | 732,643 | 769,284 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.